Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a mid-size sponsor after a complete response letter, disproportionate reporting signal workbook is the evidence after a boxed-warning proposal from the review division. 505(b)(2) development lead has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy close using disproportionate reporting signal workbook.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from disproportionate reporting signal workbook after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in disproportionate reporting signal workbook — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division conflict for 505(b)(2) development lead; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 2. Check whether disproportionate reporting signal workbook supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move the 505(b)(2) bridge is for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in disproportionate reporting signal workbook, then the action for 505(b)(2) development lead - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Missing page in disproportionate reporting signal workbook after a boxed-warning proposal from the review division, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite